Search

Your search keyword '"Sachsenmeir, Kris F."' showing total 2 results
Start Over Author "Sachsenmeir, Kris F."
2 results on '"Sachsenmeir, Kris F."'

1. Secretome screening reveals immunomodulating functions of IFNα-7, PAP and GDF-7 on regulatory T-cells

Author

Ding, Mei, Malhotra, Rajneesh, Ottosson, Tomas, Lundqvist, Magnus, Mebrathu, Aman, Brengdahl, Johan, Gehrmann, Ulf, Bäck, Elisabeth, Ross-Thriepland, Douglas, Isaksson, Ida, Magnusson, Björn, Sachsenmeir, Kris F., Tegel, Hanna, Hober, Sophia, Uhlén, Mathias, Mayr, Lorenz M., Davies, Rick, Rockberg, Johan, Holmberg Schiavone, Lovisa, Ding, Mei, Malhotra, Rajneesh, Ottosson, Tomas, Lundqvist, Magnus, Mebrathu, Aman, Brengdahl, Johan, Gehrmann, Ulf, Bäck, Elisabeth, Ross-Thriepland, Douglas, Isaksson, Ida, Magnusson, Björn, Sachsenmeir, Kris F., Tegel, Hanna, Hober, Sophia, Uhlén, Mathias, Mayr, Lorenz M., Davies, Rick, Rockberg, Johan, and Holmberg Schiavone, Lovisa

Abstract

QC 20211027

Published
2021
Full Text
View/download PDF

2. Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro.

Author

Adam PJ, Berry J, Loader JA, Tyson KL, Craggs G, Smith P, De Belin J, Steers G, Pezzella F, Sachsenmeir KF, Stamps AC, Herath A, Sim E, O'Hare MJ, Harris AL, and Terrett JA

Subjects
Breast cytology, Breast metabolism, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Cell Division drug effects, Cell Survival drug effects, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry, Organ Specificity, Proteomics, RNA, Messenger genetics, RNA, Messenger metabolism, Tumor Cells, Cultured, Up-Regulation, Arylamine N-Acetyltransferase genetics, Arylamine N-Acetyltransferase metabolism, Breast Neoplasms enzymology, Breast Neoplasms pathology, Drug Resistance, Neoplasm, Etoposide pharmacology
Abstract

Comparative two-dimensional proteome analysis was used to identify proteins differentially expressed in multiple clinical normal and breast cancer tissues. One protein, the expression of which was elevated in invasive ductal and lobular breast carcinomas when compared with normal breast tissue, was arylamine N-acetyltransferase-1 (NAT-1), a Phase II drug-metabolizing enzyme. NAT-1 overexpression in clinical breast cancers was confirmed at the mRNA level and immunohistochemical analysis of NAT-1 in 108 breast cancer donors demonstrated a strong association of NAT-1 staining with estrogen receptor-positive tumors. Analysis of the effect of active NAT-1 overexpression in a normal luminal epithelial-derived cell line demonstrated enhanced growth properties and etoposide resistance relative to control cells. Thus, NAT-1 may not only play a role in the development of cancers through enhanced mutagenesis but may also contribute to the resistance of some cancers to cytotoxic drugs.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results